BioSpace News Archive

Today, Florence announced a collaboration with Pfizer to support a global Phase 2/3 COVID-19 vaccine study.

Vibrent Health, a health technology company powering the future of precision medicine research, today announced that the National Institutes of Health (NIH) has awarded the company a new funding award to continue as the Participant Technology Systems Center (PTSC) of the All of Us Research Program.

Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it has appointed Mardi C. Dier as Executive Vice President and Chief Financial Officer (CFO), effective November 2, 2020.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in September.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease

Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc. (“VYNE Therapeutics”).

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that its Board of Directors has approved a share repurchase program of up to 1 million ordinary shares on the open market or otherwise

Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Therapeutic Goods Administration (TGA) has approved its Carillon Mitral Contour System®.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present company overviews at the following conferences being held virtually